MAPS has been working since 1992 to sponsor FDA-approved clinical studies into the safety and efficacy of botanical marijuana as a prescription medicine for specific medical uses. We’ve obtained approval from FDA and from Institutional Review Boards for several different protocols but were unable to obtain approval to purchase federally-legal marijuana from the National Institute on Drug Abuse (NIDA).
On March 14, 2014, the U.S. Public Health Service approved our request to purchase NIDA marijuana for our study of smoked whole plant (botanical) marijuana for symptoms of PTSD in U.S. veterans, an historic shift in federal policy. On December 17, 2014, MAPS was awarded a $2.15 million grant from the Colorado Department of Public Health and Environment to conduct the study. The ongoing study has received full approval from the FDA, DEA, and Institutional Review Boards (IRBs).